期刊文献+

阿德福韦在慢性乙型肝炎中的研究进展

下载PDF
导出
摘要 研究表明,如果能有效地抑制乙型肝炎病毒(HBV)的复制,就有可能减缓或停止慢性乙型肝炎(CHB)患者的疾病进展,改善患者的预后.干扰素虽然具有调节免疫功能、抗病毒的双重功效,但不良反应较多,疗效也不尽人意.核苷类药物拉米夫定是乙肝抗病毒治疗中的一个里程碑,疗效确切,耐受性和安全性良好;然而长期应用可导致患者产生耐拉米夫定HBV变异株,出现肝功能及病毒学指标的反复,甚至可能发生肝功能衰竭.阿德福韦作为一种新的抗HBV感染的核苷酸类似物已于2002年9月经美国食品药品管理局(FDA)批准在美国上市,在我国也已完成Ⅲ期临床试验,目前正式上市.现就阿德福韦在CHB中的研究应用作一综述.
出处 《上海医学》 CAS CSCD 北大核心 2006年第9期673-677,共5页 Shanghai Medical Journal
  • 相关文献

参考文献29

  • 1Dando T,Plosker G.Adefovir dipivoxil:a review of its use in chronic hepatitis B.Drugs,2003,63:2215-2234.
  • 2Cullen JM,Li DH,Brown C,et al.Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks.Antimicrob Agents Chemother,2001,45:2740-2745.
  • 3茅益民,曾民德.抗乙型病毒性肝炎新药——阿德福韦酯[J].中华肝脏病杂志,2004,12(1):61-63. 被引量:266
  • 4Delaney WE 4th,Edwards R,Colledge D,et al.Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.Antimicrob Agents Chemother,2001,45:1705-1713.
  • 5Shaw T,Locarnini SA.Hepatic purine and pyrimidine metabolism:implications for antiviral chemotherapy of viral hepatitis.Liver,1995,15:169-184.
  • 6Cundy KC.Clinical pharmacokinetics of the antiviral nucleotide analogs cidofovir and adefovir.Clin Pharmacokinet,1999,36:127-143.
  • 7Kearney B,Knight W,Currie G,et al.Adefovir dipivoxil safety and pharmacokinetics in subjects with hepatitis B virus infection and in healthy subjects.J Hepatol,2002,36(suppl.1):100.
  • 8Ono-Nita SK,Kato N,Shiratori Y,et al.Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.J Clin Invest,1999,103:1635-1640.
  • 9Neyts J,De Clercq E.Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs.Antimicrob Agents Chemother,1999,43:2885-2892.
  • 10Torresi J,locarnini S.Antiviral chemotherapy for the treatment of hepatitis B virus infections.Gastroenterology,2000,118(suppl):S83-S103.

二级参考文献29

  • 1Hadziyannis S,Tassopoulos N,Chang TT,et al.Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B patients in a long-term safety and efficacy study.J Hepatol,2004,40(Suppl 1):17 (Abstract 46).
  • 2Hadziyannis SJ,Papatheodoridis GV.Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection.Expert Rev Anti Infect Ther,2004,2:475-483.
  • 3Marcellin P,Chang TT,Lim SG,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.N Engl J Med,2003,348:808-816.
  • 4Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.N Engl J Med,2003,348:800-807.
  • 5Cullen JM,Li DH,Brown C,et al.Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks.Antimicrob Agents Chemother,2001,45:2740-2745.
  • 6Delmas J,Schorr O,Jamard C,et al.Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro.Antimicrob Agents Chemother,2002,46:425-433.
  • 7Werle-Lapostolle B,Bowden S,Locarnini S,et al.Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.Gastroenterology,2004,126:1750-1758.
  • 8Lok AS,McMahon BJ.Chronic hepatitis B:update of recommendations.Heptology,2004,39:857-861.
  • 9Qi X,Snow A,Thibault V,et al.Long-term incidence of Adefovir Dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy.Hepatol,2004,40(Suppl 1):20 (Abstract 57).
  • 10Westland CE,Yang H,Delaney WE 4th,et al.Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.Hepatology,2003,38:96-103.

共引文献409

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部